Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Chronic Stroke
NCT07053917Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of psilocybin in stroke (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Stability of systolic and diastolic blood pressure at 24 hours. Started Feb 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
stroke
Beyond the preview
Go deeper on NCT07053917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053917.